SAN FRANCISCO, Sept. 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has been selected to be one of the inaugural companies in the new NASDAQ(R) NeuroInsights(R) Neurotech Index. The Index launched today and is calculated on a price return basis (Nasdaq: NERV) and a total return basis (Nasdaq: NRVX.)
"Medivation's selection as one of the top 32 companies in the neurotechnology industry is testament to our commitment to and significant clinical progress with the development of Dimebon(TM), our investigational drug for the treatment of Alzheimer's and Huntington's diseases," said David Hung, M.D., president and chief executive officer of Medivation. "The new Neurotech Index will serve to highlight the significant companies that are changing the medical landscape for neurological diseases and conditions. We expect Medivation's inclusion in this Index to generate greater visibility for our stock."
The NASDAQ NeuroInsights Neurotech Index is the first index designed to
track the performance of leading neurotechnology companies that are listed
and actively traded on one of the three major U.S. stock exchanges. It
includes companies engaged in researching, developing, manufacturing and
marketing pharmaceuticals, biologics, medical devices and diagnostics for
the brain and nervous system. In addition to meeting minimum market
criteria, the 32 companies included in the index must be identified by
NeuroInsights as significantly involved in the neurotechnology industry,
which includes treatments and diagnostics for disorders such as
Alzheimer's, addiction, anxiety, depression, epilepsy, multiple sclerosis,
obesity, pain, Parkinson's, schizophrenia, sensory disorders, sleep
|SOURCE Medivation, Inc.|
Copyright©2007 PR Newswire.
All rights reserved